First page for those that can't see it yet, basically it puts us...

First page for those that can't see it yet, basically it puts us 1 step closer to deal with Sarepta Therapeutics

Headlines
PYC achieves major milestones towards the commercialisation of its delivery technology by:
1) Entering a new strategic partnership with the Lions Eye Institute – leading global experts in
the development of drugs for eye diseases;
2) Appointing Professor Sue Fletcher, industry leading expert in the design and development
of precision medicines, as our Chief of Research and Development on a part-time basis;
and
3) Selecting a lead drug candidate for immediate progression to clinical development - a
treatment for the leading cause of childhood blindness – a $1bn p.a. target market with
no existing treatment options – our lead drug candidate has already demonstrated
preliminary evidence of the ability to reverse this disease process in human cells (see
Figure 1 - below).
The combined impact of these developments means that:
i) PYC now has the ability to independently take drugs to market through its commercial
collaboration with the Lions Eye Institute and the appointment of Professor Fletcher;
ii) PYC has advanced from ‘platform only’ to ‘platform and product’. Previously PYC has
been advancing its cell penetrating peptide technology as a platform to deliver drugs.
Now it will be combining that technology with drugs to internally develop a new class
of therapies to cure blinding diseases of the eye;
iii) PYC will continue to commercialise its platform delivery technology either by third party
licensing arrangements or internally through additional drug development programs.
In short, these developments make PYC a drug development company whilst still retaining its core
drug delivery technology for simultaneous exploitation.